HCV reinfection after liver transplantation: Management and first experiences with telaprevir-based triple therapy;HCV-Reinfektion nach Lebertransplantation: Management und erste Ergebnisse mit der Telaprevir-basierten Triple-Therapie

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 36, 2013, Pages 1759-1764

  Herzer, K ^a   Papadopoulos Kohn A ^a   Timm, J ^a   Paul, A ^a   Jochum, C ^a   Gerken, G ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

HCV infection; hepatitis C; liver transplantation; triple therapy

Indexed keywords

TELAPREVIR;

ARTICLE; HEPATITIS C; LIVER TRANSPLANTATION; REINFECTION;

ADULT; ANTIVIRAL AGENTS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TACROLIMUS; VIRAL LOAD;

EID: 84883467354     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1349494     Document Type: Article

References (24)

1. Benito J. M., Sánchez-Parra C., Maida I. et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antivir Ther: 2013; May 3. doi: 10.3851/IMP2614 [Epub ahead of print]
2. Berenguer M., Palau A., Fernandez A. et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl: 2006; 12 1067 1076 (Pubitemid 44063780)
3. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplant: 2003; 9 S44 S47 (Pubitemid 37408002)
4. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol: 2008; 49 274 287
5. Berenguer M. Viral hepatitis: Ciclosporin versus tacrolimus for HCV transplant recipients. Nat Rev Gastroenterol Hepatol: 2012; 8 422 424
6. Burton J. R. Jr, Everson G. T. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis: 2013; 17 73 91
7. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - a potentially lethal cocktail. Hepatology: 2011; 54 3 5
8. Ciesek S., Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepatitis: 2012; 19 1 8
9. Coilly A., Roche B., Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int: 2013; 33 01 56 62
10. Cunningham M., Foster G. R. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Ther Adv Gastroent: 2012; 5 139 151
11. Garcia-Saenz-de-Sicilia M., Mukherjee S. The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice. Expert Rev Clini Pharmacol: 2012; 5 587 593
12. Hézode C., Fontaine H., Dorival C. CUPIC Study Group et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol: 2013; doi: 10.1016/j.jhep.2013.04.035 [Epub ahead of print]
13. Hsu S. H., Yeh M. L., Wang S. N. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol: 2013; 2013 890517
14. Irish W. D., Arcona S., Bowers D. et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant: 2011; 11 1676 1685
15. Joshi D., Carey I., Agarwal K. The treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Alimentary Pharmacol Ther: 2013; 37 659 671
16. Kiser J. J., Burton J. R., Anderson P. L. et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology: 2012; 55 1620 1628
17. Ogawa E., Furusyo N., Nakamuta M. et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol: 2013; May 23 doi: 10.1016/j.jhep.2013.05.017 [Epub ahead of print]
18. Pungpapong S., Aqel B. A., Koning L. et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl: 2013; 19 690 700
19. Roche B., Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int: 2012; 32 01 120 128
20. Rodriguez-Luna H., Vargas H. E. Natural history of hepatitis C and outcomes following liver transplantation. Minerva Gastroenterol Dietolog: 2004; 50 51 59 (Pubitemid 38649526)
21. Rubin A., Aguilera V., Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol: 2011; 35 805 812
22. Selzner N., Renner E. L., Selzner M. et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation: 2009; 88 1214 1221
23. Terrault N. Liver transplantation in the setting of chronic HCV. Best Practice Res Clin Gastroenterol: 2012; 26 531 548
24. Werner C. R., Egetemeyr D. P., Lauer U. M. et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl: 2012; 18 1464 1470